Foundayo Tablet, Film Coated
Product Images NDC 0002-4794

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Foundayo (NDC 0002-4794). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Foundayo (orforglipron) Tablets 0.8 mg 30 Count Package (Fou 0.8mg Cart 791057)

FOUNDAYO 0.8 mg (orforglipron) tablets film-coated oral prescription drug carton. The label shows dosage strength, NDC 0002-4178-31, and includes storage and handling instructions. Marketed by Lilly USA, LLC, Indianapolis, with a count of 30 tablets. The packaging advises to dispense with the enclosed Medication Guide.*

FDA Label Image

Foundayo (orforglipron) Tablets 14.5 mg 30 Count Package (Fou 14.5mg Cart 791070)

Packaging label for Foundayo (orforglipron) 14.5 mg film-coated tablets by Eli Lilly and Company. The label shows the product name and strength prominently, along with the NDC 0002-4839-31. It includes a visual of one oval tablet marked "L35," bottle count of 30 tablets, and storage instructions. The label also notes the product is marketed by Lilly USA, LLC and made in Ireland.*

FDA Label Image

Foundayo (orforglipron) Tablets 17.2 mg 30 Count Package (Fou 17.2mg Cart 791071)

Foundayo 17.2 mg (orforglipron) film-coated tablets packaging label. The carton displays the product name, strength, and active ingredient prominently, with 30 tablets per bottle. It includes storage instructions, recommended dosage advice, and manufacturer information from Lilly USA, LLC. The label also features a barcode and Lilly logo.*

FDA Label Image

Foundayo (orforglipron) Tablets 2.5 mg 30 Count Package (Fou 2.5mg Cart 791063)

Packaging label for Foundayo 2.5 mg tablets, oral film-coated tablets containing orforglipron, labeled for prescription use. The label includes dosage and storage instructions, manufacturer Lilly USA, LLC, and indicates 30 tablets per carton. The product is made in Ireland.*

FDA Label Image

Foundayo (orforglipron) Tablets 5.5 mg 30 Count Package (Fou 5.5mg Cart 791065)

Foundayo 5.5 mg (orforglipron) film-coated tablets packaging carton, containing 30 tablets. The label states prescription use, recommended dosage instructions, storage conditions, and that the product is marketed by Lilly USA, LLC. The label includes the NDC 0002-4794-31 and directs to dispense with the enclosed Medication Guide.*

FDA Label Image

Foundayo (orforglipron) Tablets 9 mg 30 Count Package (Fou 9mg Cart 791068)

Packaging label for Foundayo (orforglipron) tablets, 9 mg oral film-coated tablets. The label includes the product name, active ingredient, strength, NDC number 0002-4803-31, and quantity of 30 tablets. Marketed by Lilly USA, LLC, Indianapolis, Indiana, and product of Ireland. Storage and dosage instructions are also displayed.*

FDA Label Image

Chemical Structure (Fou Uspi Chem V1)

Chemical structure of orforglipron, the active ingredient in FOUNDAYO tablets. The diagram shows the molecular arrangement including fluorine atoms, various nitrogen-containing rings, and a calcium ion complex.*

FDA Label Image

Figure 1 (Fou Uspi F1 V1)

A line graph showing percentage change in body weight over 72 weeks post randomization for three dosages of FOUNDAYO tablets (5.5 mg, 9 mg, 17.2 mg) compared to placebo. The graph indicates greater weight reduction with increasing dosages of FOUNDAYO compared to minimal change with placebo. The number of patients per group is noted below the graph.*

FDA Label Image

Figure 2 (Fou Uspi F2 V1)

A line graph showing the percentage change in body weight over 72 weeks post-randomization for three dosages of FOUNDAYO tablets (5.5 mg, 9 mg, and 17.2 mg) compared to placebo. The graph depicts greater weight reduction with increasing FOUNDAYO dosages, with placebo showing minimal change. Patient numbers at various time points are noted below the x-axis.*

FDA Label Image

Figure 3 (Fou Uspi F3 V1)

A cumulative frequency chart showing the percentage change in body weight versus cumulative frequency for FOUNDAYO tablets at 5.5 mg, 9 mg, 17.2 mg doses, and placebo. The x-axis represents percent change in body weight from -55% to +35%, and the y-axis shows cumulative frequency from 0% to 100%. Different line styles distinguish each treatment group.*

FDA Label Image

Figure 4 (Fou Uspi F4 V1)

A cumulative frequency graph depicting the change in body weight percentage for FOUNDAYO tablets at strengths of 5.5 mg, 9 mg, and 17.2 mg compared to a placebo. The x-axis represents change in body weight (%) and the y-axis shows cumulative frequency (%). Four curves are plotted for FOUNDAYO 5.5 mg, FOUNDAYO 9 mg, FOUNDAYO 17.2 mg, and placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.